Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NYSE | Common Stock
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
The company offers prescription medicines for patients and physicians.
The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.
It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 29, 24 | 2.06 Increased by +12.57% | 1.96 Increased by +5.10% |
| Jul 18, 24 | 1.97 Increased by +7.65% | 1.89 Increased by +4.23% |
| Apr 23, 24 | 1.80 Increased by +5.26% | 1.69 Increased by +6.51% |
| Jan 31, 24 | 1.53 Increased by +0.66% | 1.69 Decreased by -9.47% |
| Oct 24, 23 | 1.83 Increased by +15.82% | 1.70 Increased by +7.65% |
| Jul 19, 23 | 1.83 Increased by +17.31% | 1.68 Increased by +8.93% |
| Apr 25, 23 | 1.71 Increased by +17.12% | 1.55 Increased by +10.32% |
| Feb 1, 23 | 1.52 Increased by +8.57% | 1.44 Increased by +5.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 13.17 B Increased by +8.93% | 3.19 B Increased by +81.09% | Increased by +24.21% Increased by +66.24% |
| Jun 30, 24 | 12.51 B Decreased by -10.22% | 3.25 B Increased by +40.16% | Increased by +25.94% Increased by +56.11% |
| Mar 31, 24 | 11.83 B Decreased by -10.44% | 2.69 B Increased by +17.23% | Increased by +22.72% Increased by +30.89% |
| Dec 31, 23 | 11.78 B Decreased by -10.02% | 8.48 B Increased by +478.44% | Increased by +72.01% Increased by +542.84% |
| Sep 30, 23 | 12.09 B Decreased by -5.84% | 1.76 B Increased by +11.95% | Increased by +14.56% Increased by +18.90% |
| Jun 30, 23 | 13.94 B Increased by +6.50% | 2.32 B Increased by +36.72% | Increased by +16.62% Increased by +28.37% |
| Mar 31, 23 | 13.21 B Increased by +3.07% | 2.29 B Increased by +3.20% | Increased by +17.36% Increased by +0.12% |
| Dec 31, 22 | 13.09 B Decreased by -3.22% | 1.47 B Decreased by -91.01% | Increased by +11.20% Decreased by -90.71% |